Gadodiamide is strictly for use in a medical setting, administered by qualified healthcare professionals. You will not take this medication yourself at home.

• Administration Method: It is given as a single intravenous (IV) injection directly into a vein, typically in your arm. The injection is usually performed as a rapid bolus (a quick push).
• Dosage Calculation: The dose of Gadodiamide is precisely calculated based on your body weight.
  • For CNS (brain and spine) imaging in adults and pediatric patients (2-16 years): The recommended dose is 0.2 mL/kg (0.1 mmol/kg).
  • For body imaging (intrathoracic, intra-abdominal, pelvic, retroperitoneal) in adults and pediatric patients (2-16 years):
    • For kidney imaging: 0.1 mL/kg (0.05 mmol/kg).
    • For other areas (non-cardiac intrathoracic, intra-abdominal, pelvic, retroperitoneal): 0.2 mL/kg (0.1 mmol/kg).
• Timing: The injection is carefully timed to coincide with the MRI scanning sequences to ensure optimal contrast enhancement of the targeted tissues.
• Post-Injection: After the Gadodiamide injection, a normal saline (salt water) flush is often given through the IV line to ensure complete delivery of the contrast medium and to clear the line.
• Monitoring: You will be closely monitored during and immediately after the injection for any signs of adverse reactions. The imaging procedure is typically completed within 1 hour of administration.

Gadodiamide functions by altering the magnetic properties of water molecules in your body, which are then detected by the MRI scanner to form images. It contains a gadolinium ion, which is a paramagnetic substance. When Gadodiamide is injected into your bloodstream, it quickly distributes throughout the extracellular fluid space (the fluid surrounding your cells).

Once in the tissues, the gadolinium within Gadodiamide acts as a contrast enhancer by significantly shortening the T1 relaxation time of nearby water protons. This shortening of relaxation time causes the areas where Gadodiamide has accumulated (e.g., areas with increased blood supply or compromised blood-brain barrier, like tumors or inflamed tissues) to appear much brighter on the MRI images, particularly on T1-weighted sequences. This enhanced visibility helps doctors better differentiate abnormal tissues from normal ones, leading to a clearer diagnosis. Gadodiamide is then primarily eliminated from the body via the kidneys.

• Gadodiamide contains a paramagnetic gadolinium ion.
• It shortens the T1 relaxation time of water protons.
• Causes areas of accumulation (e.g., tumors, inflammation) to appear brighter on MRI.
• Helps differentiate normal from abnormal tissues.
• Primarily eliminated by the kidneys.

Like all medications, Gadodiamide can cause side effects. Most reactions are mild and temporary. However, due to its classification as a linear GBCA, it has been particularly associated with a higher risk of a severe condition called Nephrogenic Systemic Fibrosis (NSF) in certain vulnerable patients.

Common side effects often include:

• Headache.
• Nausea.
• Dizziness or lightheadedness.
• Changes in taste (e.g., metallic taste).
• Feeling of warmth or coldness at the injection site.
• Injection site reactions: Pain, burning, or swelling at the IV site.

More serious, but less common, side effects that require immediate medical attention:

• Allergic (Hypersensitivity) Reactions: These can range from mild (rash, hives, itching) to severe, life-threatening reactions (difficulty breathing, swelling of the face/throat/tongue, severe dizziness, chest tightness, or collapse).
• Nephrogenic Systemic Fibrosis (NSF): This is a very serious and potentially fatal condition causing hardening and thickening of the skin and internal organs. It primarily affects patients with severe kidney disease. Gadodiamide carries a significant warning regarding NSF.
• Acute Kidney Injury: A sudden worsening of kidney function, especially in patients with pre-existing kidney problems.
• Seizures or convulsions.
• Changes in skin color or texture, joint stiffness, muscle weakness, deep bone pain in hips/ribs (symptoms of NSF).
• Confusion, decreased awareness, mood changes, agitation.

Report any new, unusual, or severe symptoms to the healthcare team immediately.

Due to specific safety concerns, particularly regarding kidney function, Gadodiamide carries important warnings and precautions. Your doctor and the imaging team will thoroughly assess your medical history before its administration.

• Nephrogenic Systemic Fibrosis (NSF): This is the most significant warning for Gadodiamide. It is contraindicated (should not be used) in patients with:
  • Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²).
  • Acute kidney injury. GBCAs like Gadodiamide increase the risk of NSF in these patient populations. Avoid its use unless diagnostic information is absolutely essential and unavailable with other methods. Patients at risk for reduced kidney function (e.g., over 60 years old, diabetes, hypertension) should have their kidney function tested (eGFR) before receiving Gadodiamide.
• Hypersensitivity Reactions: Allergic reactions, including severe and fatal ones, can occur. Patients with a history of allergies, asthma, or previous drug reactions are at higher risk. Emergency resuscitation equipment and personnel should be readily available.
• Not for Intrathecal Use: Gadodiamide is NEVER to be injected into the spinal canal (intrathecally). Inadvertent intrathecal use has caused serious neurological events including convulsions and coma.
• Gadolinium Retention: Gadolinium from GBCAs can be retained in various body tissues, including the brain, for prolonged periods. The long-term clinical significance of this retention is still under investigation, but it is a known phenomenon for all GBCAs, particularly linear agents like Gadodiamide.
• Pregnancy and Breastfeeding: Inform your doctor if you are pregnant or breastfeeding. Gadodiamide should be used in pregnant women only if the potential benefit outweighs the potential risk to the fetus. For breastfeeding mothers, very small amounts pass into breast milk, and a temporary interruption of breastfeeding might be considered.

• Renal Impairment: This is a critical consideration. Any medications that affect kidney function, or conditions that impair kidney function, are very important to disclose, as Gadodiamide’s elimination relies heavily on healthy kidneys.
• Allergies: A history of allergies (especially to contrast agents or dyes) is a crucial piece of information, as allergic reactions to Gadodiamide can occur.

Your healthcare team needs a comprehensive understanding of your health status and medication list to ensure the safest possible administration of Gadodiamide.

The dosage of Gadodiamide is precisely determined by the healthcare professional based on the patient’s body weight and the specific MRI indication.

• General CNS Imaging (Brain and Spine) (Adults and Pediatric Patients 2-16 years): The recommended dose is 0.1 mmol/kg (0.2 mL/kg) administered as a bolus intravenous injection.
• Body Imaging (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions) (Adults and Pediatric Patients 2-16 years):
  • For kidney imaging: 0.05 mmol/kg (0.1 mL/kg).
  • For other indicated body regions: 0.1 mmol/kg (0.2 mL/kg).
• Higher Doses: In some specific cases, for CNS imaging, a higher dose of 0.3 mmol/kg may be administered if the initial scan at 0.1 mmol/kg is inconclusive. However, higher doses increase the risk of gadolinium retention and potentially NSF.
• Infants (under 2 years): The safety and efficacy of Gadodiamide in patients younger than 2 years have not been fully established, and its use is generally contraindicated in neonates up to 4 weeks of age.
• Administration: It is administered as a single intravenous injection. To ensure complete delivery, the injection is usually followed by a 5 mL flush of 0.9% sodium chloride.
• Repeat Doses: Due to the risk of gadolinium accumulation and NSF, repeat doses within a short interval (e.g., less than 7 days) are generally discouraged. The lowest effective dose should always be used.

Always adhere to the specific dosage and administration instructions provided by your healthcare provider.

Gadodiamide (and its brand name Omniscan) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system. Its stringent prescription requirements are due to several critical factors:

• Risk of Nephrogenic Systemic Fibrosis (NSF): As a linear GBCA, Gadodiamide carries a significant risk of NSF in patients with impaired kidney function, necessitating thorough pre-screening and careful risk-benefit assessment by a medical professional.
• Intravenous Administration: It can only be administered by trained healthcare professionals in a controlled medical environment.
• Diagnostic Expertise: Its use requires the expertise of radiologists and other imaging specialists to interpret the enhanced MRI images correctly.
• Patient Monitoring: Patients must be closely monitored during and after administration for potential adverse reactions.

Therefore, a licensed medical doctor, typically a radiologist or the referring specialist, must prescribe Gadodiamide. It will be administered to you in a hospital or an accredited diagnostic imaging center under strict medical supervision and protocols. You will not receive this medication to take home.

What is Gadodiamide used for? Enhancing MRI scans of the brain, spine, and other tissues

2. What is the active ingredient? Gadodiamide

3. What drug class does it belong to? Gadolinium-based contrast agent (GBCA)

4. Is Gadodiamide a controlled substance? No

5. Is Gadodiamide available in generic form? No

6. How is Gadodiamide administered? Intravenous injection

7. What strengths are available? 287 mg/mL solution (0.5 mol/L)

8. What is the usual adult dosage? 0.1 mmol/kg body weight (0.2 mL/kg) IV

9. Can it be used in children? Yes—approved for pediatric patients ≥2 years old

10. What are common side effects? Headache, nausea, dizziness, injection site reactions

11. Can it cause serious reactions? Yes—rare cases of nephrogenic systemic fibrosis (NSF), severe allergic reactions

12. Is Gadodiamide safe during pregnancy? Use only if benefits outweigh risks; gadolinium crosses placenta

13. Is a prescription required? Yes

14. Is Gadodiamide available in Pakistan? Not widely; may be accessed via radiology specialty import

15. How should it be stored? At 20–25°C; protect from light; do not freeze

16. What precautions should be taken during use? Assess kidney function before administration; monitor for hypersensitivity

17. What are contraindications? Severe renal impairment (risk of NSF), hypersensitivity to gadodiamide

18. What monitoring is needed during use? Renal function (eGFR), allergic reactions during and after injection

19. Can Gadodiamide be combined with other contrast agents? Not recommended; use single GBCA per imaging session

20. What are similar drugs? Gadobutrol (Gadavist), Gadoterate (Dotarem), Gadoteridol (ProHance), Gadobenate (MultiHance), Gadopentetate (Magnevist)